A modification of the (75se) selenomethionine assay for the detection of complement-dependent antibody in human tumor systems
✍ Scribed by Ingalill L. Avis; Frederick P. Avis
- Publisher
- John Wiley and Sons
- Year
- 1983
- Tongue
- English
- Weight
- 409 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
A modification of Brook's prelabeling (7sSE) selenomethionine assay was developed and evaluated for detection of complement-dependent antibody (CDA) in a human tumor system. CDA was indeed detected in some breast cancer patients' sera. To determine whether the assay was reliable and reproducible, xenoantibodies were raised in rabbits by immunization with a human breast cancer line, Sk-Br-3, and tested against that line and five other unrelated human cancer lines. Multiple tests were performed on separate days. It can be concluded from the data that the assay is reliable and reproducible. The assay has wide application in investigating the biologic role of complement-dependent antibody activity in human and experimental animal tumor systems.
📜 SIMILAR VOLUMES
## Abstract NK activity of human peripheral blood lymphocytes (PBL) for cells of the human myeloid line K562, and antibody‐dependent cellular cytotoxicity (ADCC) of PBL for cells of human lung adenocarcinoma line PC‐9 were determined by the human tumor clonogenic assay (HTCA). Incubation of K562 ce
## Abstract Measuring low amounts of anti‐erythropoietin antibodies (anti‐EPO Abs) is important to evaluate the therapeutic safety of recombinant human erythropoietin (rhEPO). In this work, a simple, sensitive and high‐throughput chemiluminescent (CL) imaging assay was developed for the detection o
## Abstract Twenty‐three of 36 (64%) lung cancer patients, 19 of 36 (54%) melanoma patients and 18 of 27 (66%) sarcoma patients tested in the leukocyte migration in agarose assay against soluble extracts of histologically similar tumors showed significant inhibition of leukocyte migration. Reactivi
Monoclonal antibody (MAb) 872.3 was generated against a carcinoma metastasis and has been shown to bind with a high degree of selectivity to a tumorassociated glycoprotein (TAG-72) found in human CO- Ion and breast carcinomas, while showing minimal reactivity to any normal adult tissues. Competition
For an evaluation of the Abbott IMx Toxo IgG second generation, antibodies to Toxoplasma gondii were detected by Abbott IMx Toxo IgG and IgM, Vidas Toxo IgG and Toxo IgM (bioMérieux, France) with immunofluorescence assay verified by the dye-test for IgG, and immunosorbent agglutination assay (ISAGA)